Skip to main content

Advertisement

Table 1 Patient characteristics at baseline

From: Influence of continuous erythropoietin receptor activator (CERA) administration intervals on erythropoietic effect in hemodialysis patients

CERA dosage (μg/4 weeks) Male (%) Age (years) Diabetes (%) HD vintage (months) BUN (mg/dL) Cr (mg/dL) TP (g/dL) Alb (g/dL) Hb (g/dL) CRP (mg/dL) Fe (μg/dL) Ferritin (ng/mL) Hepcidin-25 (ng/mL)
50 (N = 25) 16 (64.0) 70.0 ± 11.3 (35–87) 13 (52.0) 105.5 ± 90.6 62.6 ± 13.6 10.7 ± 2.1 6.5 ± 0.5 3.8 ± 0.3 10.9 ± 0.8 0.35 ± 0.53 79.7 ± 26.0 (36–123) 143.2 ± 155.0 (16.1–824) 74.2 ± 41.9 (0.4–175.9)
100 (N = 13) 9 (69.2) 70.6 ± 7.7 (53–85) 4 (30.8) 67.4 ± 66.4 67.5 ± 14.2 10.4 ± 1.9 6.7 ± 0.3 3.7 ± 0.3 11.0 ± 0.7 0.25 ± 0.52 82.1 ± 31.7 (32–145) 89.1 ± 70.4 (25.1–233) 38.9 ± 33.6 (0.2–122)
150 (N = 6) 5 (83.3) 69.0 ± 9.3 (51–75) 5 (83.3) 88.5 ± 45.4 57.9 ± 23.2 9.1 ± 4.0 6.6 ± 0.4 3.3 ± 0.2 10.4 ± 1.0 2.46 ± 3.17 44.8 ± 15.8 (26–68) 128.6 ± 89.6 (54.6–263) 90.2 ± 29.3 (55.7–137.1)
All (N = 44) 30 (68.2) 70.0 ± 9.9 (35–87) 22 (50.0) 91.9 ± 79.6 63.4 ± 15.2 10.4 ± 2.4 6.6 ± 0.4 3.7 ± 0.3 10.9 ± 0.8 0.61 ± 1.40 75.6 ± 29.0 (26–145) 125.2 ± 127.7 (16.1–824) 66.0 ± 41.7 (0.2–175.9)
  1. Variables are represented as mean ± standard deviation
  2. HD hemodialysis, BUN blood urea nitrogen, Cr creatinine, TP total protein, Alb albumin, Hb hemoglobin, CRP C-reactive protein, Fe iron